• All categories
  • Newsletters
  • Podcasts
  • Position & Policy Papers
  • Reports
  • Statements
  • Consultation Responses
  • News Release
  • Opinion







Will transparency of R&D costs lead to more affordable medicines?

Without clear knowledge of pharmaceutical R&D costs, it is virtually impossible for regulators to design...

What could change in the fight against medicine shortages in Europe?

With the COVID-19 pandemic and the multiplication of antibiotic supply disruptions, the fight against medicine...

Academic development of medicines – a path to solving unmet medical needs

By Dr Ward Rommel, Chair, Access to Medicines Task Force of Association of European Cancer...

CSOs call on the European Commission to publish revised EU pharmaceutical legislation no later than in March 2023

Brussels, 9 March 2023 Dear Commissioner Kyriakides, We, the signatory organisations representing civil society, patients,...

EPF and EPHA met with Commissioners Schinas and Kyriakides to discuss the ongoing pharmaceutical legislation revision and medicine shortages

Brussels, 7 March 2023  Yesterday afternoon, the European Public Health Alliance (EPHA) and the European...

Joint letter | The shortage of antibiotics should be considered a “major event”

To the EMA Executive DirectorTo the members of the Executive Steering Group on Shortages and...

The need for more balance, transparency, and accountability in the pharmaceutical sector

While the COVID-19 pandemic has brought access and affordability of medicines to the spotlight, it...

Towards sustainable access to healthcare: patient-centred, needs-driven, and evidence-based

Access is at the crossroad of innovation, strong evidence, affordable prices and societal needs.

Get the EPHA Newsletter

Get involved !

Get involved !

Sign up here to receive our updates on European health policy and invitations to our events.

Subscribe now

You have Successfully Subscribed!